Sandra Horning, MD
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of alectinib (Alecensa) for the first-line treatment of adults with ALK-positive, advanced non–small cell lung cancer (NSCLC).
The most common grade ≥3 AEs (≥5%) in the alectinib arm were increased alanine transferase and aspartate transferase (5%) and decreased red blood cells (5%). Patients assigned to crizotinib were more likely to discontinue treatment due to AEs (13% vs 11%), and more likely to experience dose reduction (21% vs 16%) and dose interruption (25% vs 19%).
CHMP recommends EU approval of Roche’s Alecensa (alectinib) as a first-line treatment for people with ALK-positive NSCLC. Roche. http://bit.ly/2xEeXwm. Accessed October 13, 2017.
... to read the full story